CID-1067700 (Synonyms: ML-282) |
Catalog No.GC12948 |
Le CID-1067700 (ML282) est un inhibiteur de la pan GTPase et inhibe de manière compétitive le Ras lié dans le cerveau 7 (Rab7) avec un Ki de 13 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 314042-01-8
Sample solution is provided at 25 µL, 10mM.
CID-1067700 is the first competitive inhibitor of nucleotide binding by Ras-related GTPases [1].
The Ras superfamily of GTPases, which includes Arf, Rho, Ras and Rab GTPase subfamilies, regulate many cellular processes ranging from membrane trafficking to the control of cell proliferation. Alteration of small GTPase functions is a hallmark of genetic and sporadic human diseases, making GTPase family members attractive targets [1].
CID-1067700 is a competitive inhibitor of nucleotide binding by Ras-related GTPases. CID-1067700 exhibited EC50 values of 20-500 nM and at least 40% inhibitory activity against all tested GTPases. CID-1067700 significantly inhibited Rab GTPases (Rab2 and Rab7). CID 1067700 inhibited Rab7 binding of the BODIPY-linked nucleotides with EC50 values and Ki values of 11.22 ± 1.34 nM and 12.89 nM for BODIPY-GTP, and 20.96 ± 1.34 nM and 19.70 nM for BODIPY-GDP, respectively. The maximal inhibitory response was ≥97% for both nucleotides [1].
Reference:
[1]. Agola JO, Hong L, Surviladze Z, et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol. 2012 Jun 15;7(6):1095-108.
Cell experiment: | To treat human and mouse B cells in vitro with the Rab7 inhibitor, CID-1067700 is diluted in DMSO and added to cell cultures to the final concentration of 40 μM. CID-1067700 or DMSO is added either at the time when B cell stimulation started, or 66 h after B cells are stimulated with LPS plus IL-4, TGF-β, anti-δ/dex and RA, for analysis of plasma cell survival[2]. |
Animal experiment: | Mice[2]For in vivo treatment, CID-1067700 dissolved in DMSO (stock concentration 40 mM, 16 mg/mL) is diluted with the solvent to the final volume of 50 μL and injected intraperitoneally (i.p.) once per week at the dose of 16 mg/kg body weight. C57, MRL/Faslpr/lpr and C57/Sle1Sle2Sle3 mice injected i. p. with the vehicle DMSO (50 μL). For survival studies and skin lesion analyses, MRL/Faslpr/lpr mice are treated with nil or CID-1067700 for 10 weeks and maintained until moribund (e.g., showing signs of severe loss of mobility, hunched back, piloerection, ruffled fur, dyspnea, gasping and weight loss), at which point they are euthanized[2]. |
References: [1]. Agola JO, et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol. 2012 Jun 15;7(6):1095-108. |
Cas No. | 314042-01-8 | SDF | |
Synonymes | ML-282 | ||
Chemical Name | 2-[[(benzoylamino)thioxomethyl]amino]-4,7-dihydro-5,5-dimethyl-5H-thieno[2,3-c]pyran-3-carboxylic acid | ||
Canonical SMILES | O=C(NC(NC1=C(C(O)=O)C(CC(C)(C)OC2)=C2S1)=S)C3=CC=CC=C3 | ||
Formula | C18H18N2O4S2 | M.Wt | 390.5 |
Solubility | ≤10mg/ml in DMSO | Storage | Store at 2-8°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.5608 mL | 12.8041 mL | 25.6082 mL |
5 mM | 0.5122 mL | 2.5608 mL | 5.1216 mL |
10 mM | 0.2561 mL | 1.2804 mL | 2.5608 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 32 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *